Today: 1 March 2026
Subscribe
Browse Category

NYSE:MRK 11 August 2025 - 25 November 2025

Dow 30 Today (24 November 2025): Merck and Caterpillar Lead 200‑Point Dow Jones Rally on Fed Rate‑Cut Bets

Dow 30 Today (24 November 2025): Merck and Caterpillar Lead 200‑Point Dow Jones Rally on Fed Rate‑Cut Bets

The Dow Jones Industrial Average rose 202.86 points, or 0.44%, to 46,448.27 on Monday, as investors bet on a December Fed rate cut amid a government data blackout. The Nasdaq jumped 2.69% and the S&P 500 gained 1.55%. Treasury yields slipped to around 4.03%. The Bureau of Labor Statistics canceled the October CPI release due to the federal shutdown.
25 November 2025
·········
MRK Stock Today: Merck Jumps on Wells Fargo Upgrade and Keytruda Momentum (November 24, 2025)

MRK Stock Today: Merck Jumps on Wells Fargo Upgrade and Keytruda Momentum (November 24, 2025)

Merck shares climbed nearly 4% to around $101.40 by early afternoon Monday, nearing 2025 highs after Wells Fargo upgraded the stock to “Overweight” and raised its price target to $125. The move followed new FDA approvals and pipeline updates. Options activity surged, with call volume outpacing puts more than 3:1. Merck’s market cap stood at about $252 billion.
24 November 2025
··
Merck Stock Jumps on Wells Fargo Upgrade and New Keytruda Wins – MRK Today, November 24, 2025

Merck Stock Jumps on Wells Fargo Upgrade and New Keytruda Wins – MRK Today, November 24, 2025

Merck shares jumped about 4% to $101.97 on Monday after Wells Fargo upgraded the stock and raised its price target to $125. The move followed new data on Merck’s hematology pipeline, another FDA approval for Keytruda in bladder cancer, and increased institutional buying. MRK traded at its highest level since January, with technical indicators signaling overbought conditions.
24 November 2025
·
Merck (MRK) Stock Today: Mini‑Tender Warning, Dividend Hike and Drug Wins – 22 November 2025

Merck (MRK) Stock Today: Mini‑Tender Warning, Dividend Hike and Drug Wins – 22 November 2025

Merck urged shareholders to reject Tutanota LLC’s unsolicited mini-tender offer of $65 per share, about 25–32% below recent prices. The company raised its quarterly dividend to $0.85 and reported FDA approval for new Keytruda-based bladder cancer treatments. Merck stock traded near $97.76 Friday, up 2.9%, with a market cap of $243 billion.
22 November 2025
···
Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck (MRK) Stock Today, Nov 18, 2025: Shares Jump on Winrevair Phase 2 Win as Cidara Deal Builds Flu Portfolio

Merck shares rose about 3%–4% Tuesday after the company said its drug Winrevair met the main goal in a Phase 2 study for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction. Merck plans to advance the drug to Phase 3 trials. The update follows last week’s $9.2 billion deal to acquire Cidara Therapeutics.
18 November 2025
··
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Merck’s $9.2 Billion Bid Sends Cidara Therapeutics (CDTX) Soaring 105% on November 14, 2025

Merck said it will acquire Cidara Therapeutics for $221.50 per share in cash, valuing the deal at about $9.2 billion. The offer represents a 109% premium to Cidara’s last closing price and sent CDTX shares up more than 100%. Both companies’ boards approved the deal, which is expected to close in early 2026 pending regulatory clearance. Merck aims to secure Cidara’s lead flu-prevention drug, CD388.
14 November 2025
··
5 NYSE Stocks to Watch Today (November 14, 2025): WMT, MRK, BMY, NSC, VRT

5 NYSE Stocks to Watch Today (November 14, 2025): WMT, MRK, BMY, NSC, VRT

Walmart shares dropped up to 3% after the company named John Furner as CEO, replacing Doug McMillon effective February 2026. Merck agreed to buy Cidara Therapeutics for $9.2 billion in cash, gaining access to a late-stage flu prevention drug. U.S. equity futures fell sharply as tech stocks continued to slide and traders lowered expectations for a near-term Fed rate cut.
14 November 2025
·····
Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck will acquire Cidara Therapeutics for about $9.2 billion, paying $221.50 per share in cash—a 109% premium to Cidara’s last close. The deal gives Merck rights to CD388, a Phase 3 long-acting flu prevention drug. Cidara shares doubled in pre-market trading. The transaction is expected to close in Q1 2026, pending approvals.
14 November 2025
···
Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck shares rose Wednesday after Phase 3 data showed its oral PCSK9 inhibitor enlicitide cut LDL-C by up to 59.7% and matched placebo for safety. The FDA also cleared Promega’s OncoMate MSI Dx as a companion diagnostic for Keytruda plus Lenvima in advanced endometrial carcinoma. JAMA published peer-reviewed results for enlicitide in HeFH.
12 November 2025
··
Dow Falls as Palantir Plunges – Is the AI Stock Boom Turning into a Bubble?

Dow Falls as Palantir Plunges – Is the AI Stock Boom Turning into a Bubble?

The Dow fell 0.5% Monday as UnitedHealth and Merck dropped, while the Nasdaq rose 0.5% on Amazon’s 4% jump after a $38 billion OpenAI deal. Palantir slid 8% despite beating revenue estimates, dragging other AI stocks lower. Wall Street leaders and Michael Burry warned of an AI-driven bubble and possible correction. Investors showed caution as weak manufacturing data and Fed policy jitters reversed early gains.
4 November 2025
·········
Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Stock Dips on Earnings Beat — Will Pipeline Boost Spur a Rally?

Merck shares fell about 2% after hours Oct. 30 despite Q3 revenue of $17.28 billion and $2.58 adjusted EPS, both above estimates. Keytruda sales rose 10% to $8.1 billion. The company narrowed its 2025 sales outlook and raised profit guidance. Recent milestones include FDA approval of subcutaneous Keytruda and the $10 billion acquisition of Verona Pharma.
30 October 2025
···
Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

Pfizer’s sickle cell drug inclacumab failed a Phase 3 trial, missing its main goal and deepening setbacks from its $5.4 billion Global Blood Therapeutics acquisition. In contrast, Pfizer and Merck’s Padcev-Keytruda combo improved survival in muscle-invasive bladder cancer. Novo Nordisk’s Wegovy won FDA approval for treating metabolic dysfunction-associated steatohepatitis.
17 August 2025
······
Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

Novartis said two Phase III trials of ianalumab met primary endpoints in Sjögren’s disease, showing significant disease activity reduction. Boehringer Ingelheim’s zongertinib won accelerated FDA approval for HER2-mutant NSCLC. GSK’s gepotidacin received FDA Priority Review for uncomplicated gonorrhea. The U.S. Postal Service began blocking shipments of illicit vaping products amid regulatory scrutiny.
11 August 2025
····
1 … 5 6 7
Go toTop